
Overview of Dr. DeRubertis
Dr. Brian DeRubertis is a vascular surgeon and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian Brooklyn Methodist Hospital, and New York-Presbyterian Queens. He received his medical degree from Weill Cornell Medicine and has been in practice 29 years. Dr. DeRubertis accepts several types of health insurance, listed below. He is one of 64 doctors at New York-Presbyterian Hospital and one of 29 doctors at NewYork-Presbyterian Brooklyn Methodist Hospital who specialize in Vascular Surgery. He has more than 90 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Columbia and Cornell Campus)Fellowship, Vascular Surgery - Independent, 2005 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2002 - 2005
Oregon Health & Science University (OHSU Health)Residency, Surgery, 1997 - 2002
Weill Cornell MedicineClass of 1997
Certifications & Licensure
OR State Medical License 1998 - Present
NY State Medical License 2000 - 2027
CA State Medical License 2007 - 2023
American Board of Surgery Vascular Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- Response by DeRubertis et al to Letter Regarding Article, "Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-...Brian G DeRubertis, Sahil A Parikh, Ramon L Varcoe,
Circulation. 2026-08-04 - Smoking Status Predicts Mortality after Carotid Endarterectomy for Symptomatic Disease but Not after Carotid Stenting or Transcarotid Revascularization.Mark Basilious, Izzet Akosman, Nakia Sarad, Nitin Jethmalani, Christopher J Agrusa
Annals of Vascular Surgery. 2026-08-01 - 1 citationsLong-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.Sahil A Parikh, Brian G DeRubertis, Marc P Bonaca, Prakash Krishnan, Richard H Pin
Journal of the American College of Cardiology. 2026-07-07
Authored Content
- Peripheral Drug Delivery Devices: Where Do We Stand?September 2025
- Surveying the Below-the-Knee Revascularization Trial LandscapeMay 2024
- Lower Extremity TechniquesSeptember 2023
Press Mentions
LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTIOctober 27th, 2025
Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold System Approved in CanadaOctober 2nd, 2025
Abbott’s Dissolving Stent Receives Health Canada Approval for Treating Blocked Arteries Below-the-KneeSeptember 29th, 2025
Grant Support
- Preventing major amputations and preserving functional limbs in no option critical limb-threating ischemia patientsAVEERA MEDICAL INC.2025–2027
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPOFirst Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: